Is NCT05647265 recruiting in Anchorage, AK?

Yes, NCT05647265 is currently recruiting participants at its Anchorage, AK location. This sarcomatoid mesothelioma clinical trial is actively enrolling qualified participants.

How do I join the sarcomatoid mesothelioma clinical trial in Anchorage?

To join this clinical trial in Anchorage, complete the eligibility form on this page. A study coordinator will contact you to discuss next steps and determine if you qualify.

Is participation in this Anchorage clinical trial free?

Yes, all study-related care is provided at no cost to qualified participants. Many studies also offer compensation for time and travel expenses.

Sarcomatoid Mesothelioma Clinical Trial in Anchorage, AK

About This Sarcomatoid Mesothelioma Study in Anchorage

This phase II trial evaluates the safety and effectiveness of giving immunotherapy (nivolumab and ipilimumab) before surgery for controlling disease in patients with stage I-IIIa sarcomatoid mesothelioma. Immunotherapy with monoclonal antibodies, such as nivolumab and ipilimumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving immunotherapy before surgery may be more effective at controlling disease in patients wit

Sponsor: Alliance for Clinical Trials in Oncology

Who Can Participate

Inclusion Criteria

Sarcomatoid or sarcomatoid-dominant (\> 50%) biphasic, pleural mesothelioma

Stage: I-IIIA disease per Union for International Cancer Control (UICC) TNM Classification of Malignant Tumours 8th edition

Measurable disease or non-measurable disease as defined

No prior treatment which would be considered treatment for the primary neoplasm or impact the primary endpoint

No treatment with hormones or other chemotherapeutic agents except for hormones administered for non-disease-related conditions (e.g., insulin for diabetes and or hormonal therapy for breast, prostate cancer etc.)

Not pregnant and not nursing, because this study involves an investigational agent whose genotoxic, mutagenic and teratogenic effects on the developing fetus and newborn are unknown \

Therefore, for women of childbearing potential only, a negative pregnancy test done =\< 14 days prior to registration is required

Age \>= 18 years

Eastern Cooperative Oncology Group (ECOG) performance status =\< 2 or Karnofsky \>= 60%

Absolute neutrophil count (ANC) \>= 1,000/mm\^3

Leukocytes \>= 2,000/mm\^3

Platelet count \>= 100,000/mm\^3

Creatinine =\< 1.5 x upper limit of normal (ULN) OR creatinine clearance \>= 40 mL/min

Total bilirubin =\<1.5 x ULN, except patients with Gilbert Syndrome who can have total bilirubin \< 3.0 mg/dl

Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =\< 3.0 x ULN

Alkaline (alk) phosphatase (phos) =\< 3.0 x ULN

No active, known or suspected autoimmune disease except for vitiligo, type I diabetes mellitus, residual hypothyroidism due to autoimmune condition only requiring hormone replacement, psoriasis not requiring systemic treatment, or conditions not expected to recur in the absence of an external trigger

No active systemic infection requiring therapy, as well as positive tests for hepatitis B surface antigen or hepatitis C antibody

No history of any other condition that may require the initiation of anti-tumor necrosis factor alpha (TNFalpha) therapies or other immunosuppressant medications during the study

Human immunodeficiency virus (HIV)-infected patients on effective anti-retroviral therapy with undetectable viral load within 6 months are eligible for this trial

Patients with known history or current symptoms of cardiac disease, or history of treatment with cardiotoxic agents, should have a clinical risk assessment of cardiac function using the New York Heart Association Functional Classification. To be eligible for this trial, patients should be class 2B or better

Patients with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen are eligible for this trial

STEP 2 ELIGIBILITY CRITERIA: Completion of at least 1 cycle of treatment and not have an unresolved adverse event that would preclude surgery

STEP 2 ELIGIBILITY CRITERIA: No evidence of progression that would preclude resection

STEP 2 ELIGIBILITY CRITERIA: ECOG performance status =\< 2 or Karnofsky \>= 60%

STEP 2 ELIGIBILITY CRITERIA: Predicted forced expiratory volume in 1 second (FEV1) \> 35% and postoperative predicted diffusion capacity of the lung for carbon monoxide (DLCO) \> 35%

STEP 2 ELIGIBILITY CRITERIA: Registration to step 2 no less than 21 days and no more than 90 days after the last dose of neoadjuvant therapy

Exclusion Criteria

No patients deemed to be unresectable or poor surgical candidates

No patients with chest wall invasion, peritoneal spread, contralateral pleural involvement, mediastinal organ involvement, vertebral involvement, or metastases to contralateral intrathoracic lymph nodes, or any supraclavicular nodes

No patients with a history of symptomatic interstitial lung disease

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Anchorage?

Yes, this clinical trial (NCT05647265) has an active research site in Anchorage, AK that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Sarcomatoid Mesothelioma Treatment Options in Anchorage, AK

If you're searching for sarcomatoid mesothelioma treatment options in Anchorage, AK, this clinical trial (NCT05647265) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Anchorage research site is actively enrolling participants for this phase 2 clinical trial. You'll receive care from experienced sarcomatoid mesothelioma specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all sarcomatoid mesothelioma clinical trials near you to find additional studies recruiting in your area.

Sarcomatoid Mesothelioma Clinical Trial in Anchorage, AK

Expert Care in Anchorage

IRB Approved

No-Cost Care

Apply for This Anchorage Location

Why Participate?

Simple Process